Hematologic Malignancies | CHOP Research Institute
 

Hematologic Malignancies

The Maude Lab for Acute Lymphoblastic Leukemia Therapies focuses on developing and clinically evaluating new immunotherapies and targeted cancer therapies for children with high-risk and relapsed/refractory acute lymphoblastic

Published on
Jun 22, 2023
Wei Tong, PhD, and colleagues found a protein interaction that appears to be a driver of hematologic malignancies.

The Barrett Lab studies the immune function of children with cancer.  This research program takes two paths: investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.

The Aplenc Lab investigates ways to improve the outcomes of children with cancer, particularly acute myeloid leukemia, through translational studies, patient-centered outcomes research, and with clinical epidemiology studies.

Dr. Rheingold's research interests center on acute lymphocytic leukemia, and she serves on the Children's Oncology Group's Relapsed ALL, Infant ALL, and Complementary Therapies committees. In addition, she is investigates complementary and alternative therapies, supportive care for oncology patients undergoing chemotherapy, medical education, and rare childhood tumors.

E-mail:
rheingold [at] chop.edu

Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.

E-mail:
barrettd [at] chop.edu

Dr. Aplenc investigates ways to improve the outcomes of children with cancer, particularly acute myeloid leukemia, with clinical epidemiology studies and translational research.

E-mail:
aplenc [at] chop.edu